Drug Profile
Research programme: antibody therapeutics - Adimab/Sanofi
Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Adimab; Sanofi
- Class Antibodies; Bispecific antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Unspecified in USA
- 06 Feb 2015 Early research in Undefined indication in USA (unspecified route)